Attached files

file filename
EX-99.2 - PRESENTATION MATERIALS - UNIGENE LABORATORIES INCex99-2.htm
EX-99.1 - PRESS RELEASE - UNIGENE LABORATORIES INCex99-1.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
 
FORM 8-K
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):
September 14, 2010
______________
Unigene Laboratories, Inc.
(Exact name of registrant as specified in its charter)
 
Delaware
0-16005
22-2328609
(State or other jurisdiction of
incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
     
81 Fulton Street, Boonton, New Jersey
07005
(Address of principal executive offices)
(Zip Code)
 
(973) 265-1100
(Registrant’s telephone number, including area code)
 
Not Applicable
(Former name, former address and former fiscal year, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
¨
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
¨
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
¨
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 


 
 

 

Section 7 – Regulation FD

Item 7.01. Regulation FD Disclosure.

On September 14, 2010, Unigene Laboratories, Inc. (the “Company”) issued a press release concerning its corporate strategy and corporate realignment.  The Company expects to make a presentation concerning these topics at the Rodman & Renshaw 12th Annual Healthcare Conference on September 14, 2010.  A copy of the press release and the slides are furnished as Exhibits 99.1 and 99.2, respectively, to this report.
 
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
 
***
 
By filing this Current Report on Form 8-K, the Company makes no admission as to the materiality of any information in this report.  The information contained in this Current Report on Form 8-K is intended to be considered in the context of the Company’s filings with the Securities and Exchange Commission (the “SEC”) and other public announcements that the Company makes, by press release or otherwise, from time to time.  Except as required by applicable law, the Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is appropriate.  Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.


Section 9 – Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits.
 
(d)           Exhibits

 Exhibit No.
Document Description
     99.1
      Press Release dated September 14, 2010
     99.2
      Presentation Materials dated September 14, 2010

 
2

 

Signatures
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 

 
UNIGENE LABORATORIES, INC.
   
   
 
By:
/s/ William Steinhauer
 
William Steinhauer, Vice President of Finance
   
   
   
Date:       September 14, 2010
   


 
3

 

EXHIBIT INDEX

 Exhibit No.
Document Description
     99.1
      Press Release dated September 14, 2010
     99.2
      Presentation Materials dated September 14, 2010
 
 
 
4